BiotechTube
Home/ArriVent Biopharma/Winston Kung, MBA
WK

Winston Kung, MBA

Chief Financial Officer

ArriVent Biopharma

Therapeutic Areas

Oncology

ArriVent Biopharma Pipeline

DrugIndicationPhase
Firmonertinib1L NSCLC with EGFR Exon 20 Insertion MutationsPhase 3
Firmonertinib + SHP2 inhibitor2L+ NSCLC with EGFR Classical MutationsPhase 1
ARR-217Gastrointestinal (GI) TumorsPreclinical
ARR-002Solid TumorsDiscovery
ARR-421Solid TumorsDiscovery
ARR-173Solid TumorsDiscovery

Leadership Team at ArriVent Biopharma

Z(
Zhengbin (Bing) Yao, PhD
Chief Executive Officer & Chairman
SL
Stuart Lutzker, MD, PhD
President, Research & Development
RL
Robin LaChapelle, MA
Chief Operating Officer
YW
Yang Wang, PhD
Chief Technology Officer
JK
James Kastenmayer, PhD, JD
General Counsel
BR
Brent Rice
Chief Commercial Officer
View full ArriVent Biopharma profile